We are live on
!
Find out more
TCG Crossover Management Portfolio holdings
AUM
$4.16B
Turnover
31.15%
1-Year Est. Return
983.43%
This Fund
S&P 500
This Quarter
Est. Return
+38.46%
1 Year Est. Return
+983.43%
3 Year Est. Return
+3,012.95%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$1.26B
AUM Growth
+$363M
(+40%)
Cap. Flow
+$234M
Cap. Flow
% of AUM
18.46%
Top 10 Holdings %
Top 10 Hldgs %
58.32%
Holding
38
New
9
Increased
5
Reduced
7
Closed
5
Avg Time Held
0.8
years
Top 10 Avg Time Held
0.6
years
Top 20 Avg Time Held
0.9
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
CG Oncology
CGON
|
+$146M |
| 2 |
Astria Therapeutics
ATXS
|
+$65.7M |
| 3 |
Keros Therapeutics
KROS
|
+$52.1M |
| 4 |
Mineralys Therapeutics
MLYS
|
+$39.3M |
| 5 |
Ocular Therapeutix
OCUL
|
+$37.7M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ICVX
Icosavax, Inc. Common Stock
ICVX
|
+$58.4M |
| 2 |
RayzeBio, Inc. Common Stock
RYZB
|
+$54.1M |
| 3 |
GRCL
Gracell Biotechnologies Inc. American Depositary Shares
GRCL
|
+$45.3M |
| 4 |
KalVista Pharmaceuticals
KALV
|
+$29.8M |
| 5 |
Structure Therapeutics
GPCR
|
+$21.6M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
1
CG Oncology
CGON
$5.48B
| $157M | 12.39% |
+3,570,206
| New | +$146M |
2024 Q1
0 quarters
|
|
2
Dyne Therapeutics
DYN
$2.81B
| $75.2M | 5.95% |
2,650,150
+1,000,000
| +61% | +$22.6M |
2023 Q1
4 quarters
|
|
|
3
DELISTED
Astria Therapeutics
ATXS
| $74.3M | 5.87% |
+5,278,928
| New | +$65.7M |
2024 Q1
0 quarters
|
|
4
Silence Therapeutics
SLN
$558M
| $71.2M | 5.63% |
3,295,350
+1,190,475
| +57% | +$25.9M |
2022 Q3
6 quarters
|
|
|
5
Structure Therapeutics
GPCR
$1.56B
| $68.5M | 5.42% |
1,598,421
-511,163
| -24% | -$21.6M |
2023 Q1
4 quarters
|
|
6
Jade Biosciences
JBIO
$855M
| $65.1M | 5.15% |
62,894
| – | – |
2021 Q4
9 quarters
|
|
7
DELISTED
Inhibrx, Inc. Common Stock
INBX
| $61.2M | 4.84% |
1,750,387
| – | – |
2023 Q3
2 quarters
|
|
|
8
Keros Therapeutics
KROS
$219M
| $58.2M | 4.6% |
+879,344
| New | +$52.1M |
2024 Q1
0 quarters
|
|
9
Geron
GERN
$765M
| $57.4M | 4.54% |
17,391,639
-5,984,200
| -26% | -$13.4M |
2022 Q1
8 quarters
|
|
10
Savara
SVRA
$978M
| $49.8M | 3.94% |
10,000,000
| – | – |
2023 Q3
2 quarters
|
|
|
11
Ocular Therapeutix
OCUL
$1.58B
| $48.4M | 3.83% |
+5,319,148
| New | +$37.7M |
2024 Q1
0 quarters
|
|
12
Cogent Biosciences
COGT
$4.88B
| $41.8M | 3.3% |
6,214,375
+583,333
| +10% | +$3.61M |
2021 Q4
9 quarters
|
|
13
Edgewise Therapeutics
EWTX
$4.02B
| $41.5M | 3.28% |
+2,272,728
| New | +$36.1M |
2024 Q1
0 quarters
|
|
|
14
Mineralys Therapeutics
MLYS
$1.84B
| $41.1M | 3.25% |
+3,185,185
| New | +$39.3M |
2024 Q1
0 quarters
|
|
15
Madrigal Pharmaceuticals
MDGL
$10.6B
| $39.9M | 3.15% |
149,283
-30,634
| -17% | -$7.22M |
2022 Q3
6 quarters
|
|
16
DELISTED
Tourmaline Bio
TRML
| $33.8M | 2.68% |
1,477,593
+469,691
| +47% | +$16.6M |
2023 Q4
1 quarter
|
|
17
Tyra Biosciences
TYRA
$1.29B
| $32.6M | 2.58% |
1,989,103
| – | – |
2021 Q4
9 quarters
|
|
18
Compass Pathways
CMPS
$1.56B
| $32.1M | 2.54% |
3,858,000
| – | – |
2023 Q3
2 quarters
|
|
19
Kura Oncology
KURA
$855M
| $30.4M | 2.4% |
1,423,642
| – | – |
2022 Q1
8 quarters
|
|
20
Tarsus Pharmaceuticals
TARS
$3.38B
| $28.9M | 2.28% |
793,829
-349,028
| -31% | -$10.3M |
2023 Q3
2 quarters
|
|
21
DELISTED
Adverum Biotechnologies
ADVM
| $28.4M | 2.25% |
+2,008,340
| New | +$30.5M |
2024 Q1
0 quarters
|
|
22
DELISTED
Soleno Therapeutics
SLNO
| $23.5M | 1.86% |
+550,000
| New | +$24.9M |
2024 Q1
0 quarters
|
|
|
CNTA
23
DELISTED
Centessa Pharmaceuticals
CNTA
| $23.1M | 1.82% |
2,040,816
| – | – |
2023 Q3
2 quarters
|
|
24
Abivax
ABVX
$7.68B
| $15.7M | 1.24% |
1,100,000
| – | – |
2023 Q4
1 quarter
|
|
25
VistaGen Therapeutics
VTGN
$9.17M
| $14.1M | 1.12% |
2,676,580
| – | – |
2023 Q4
1 quarter
|
|
Similar funds
CCMIC
TCG Crossover Management's Q1 2024 Portfolio in Review
As of Q1 2024, TCG Crossover Management held 38 positions worth $1.26B, up 40% from $902M the previous quarter. Its ten largest holdings account for 58% of the portfolio.
TCG Crossover Management deployed $234M of net new capital in Q1 2024, opening 9 new positions and adding to 5 existing holdings. Its largest new stake was CG Oncology: 3,570,206 shares worth $157M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.
On the sell side, the largest reduction was KalVista Pharmaceuticals, an estimated $29.8M trimmed.
- TCG Crossover Management's largest Q1 2024 buy was CG Oncology: 3,570,206 shares worth $157M.
- TCG Crossover Management added most to Silence Therapeutics in Q1 2024, an estimated $25.9M increase.
- TCG Crossover Management's biggest Q1 2024 reduction was KalVista Pharmaceuticals, cutting an estimated $29.8M.
- TCG Crossover Management fully exited Icosavax, Inc. Common Stock in Q1 2024, selling an estimated $58.4M.
- TCG Crossover Management's ten largest holdings make up 58% of its $1.26B portfolio in Q1 2024.
- TCG Crossover Management opened 9 new positions and closed 5 in Q1 2024.
- TCG Crossover Management's portfolio value rose 40% quarter-over-quarter to $1.26B.
Based on TCG Crossover Management's 13F filing for Q1 2024, filed 15 May 2024.